117 related articles for article (PubMed ID: 20371218)
1. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
Henríquez-Hernández LA; Pérez LF; Hernández AG; de León AC; Díaz-Chico B; Rosales AM
Cancer Epidemiol; 2010 Aug; 34(4):490-3. PubMed ID: 20371218
[TBL] [Abstract][Full Text] [Related]
2. Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy.
Henríquez-Hernández LA; Murias-Rosales A; González-Hernández A; de León AC; Díaz-Chico N; Fernández-Pérez L
Cancer Epidemiol; 2010 Oct; 34(5):634-8. PubMed ID: 20638924
[TBL] [Abstract][Full Text] [Related]
3. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
4. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
5. Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
Huang MY; Wang YH; Chen FM; Lee SC; Fang WY; Cheng TL; Hou MF; Wang JY; Lin SR
Ann Surg Oncol; 2008 Mar; 15(3):872-80. PubMed ID: 18095031
[TBL] [Abstract][Full Text] [Related]
6. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study.
Henríquez-Hernández LA; Murias-Rosales A; Hernández González A; Cabrera De León A; Díaz-Chico BN; Mori De Santiago M; Fernández Pérez L
Oncol Rep; 2009 Dec; 22(6):1425-33. PubMed ID: 19885596
[TBL] [Abstract][Full Text] [Related]
7. Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancer.
Shitara K; Muro K; Ito S; Sawaki A; Tajika M; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Matsuo K
Cancer Epidemiol Biomarkers Prev; 2010 May; 19(5):1311-9. PubMed ID: 20447923
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.
Grieu F; Powell B; Beilby J; Iacopetta B
Anticancer Res; 2004; 24(5B):3215-9. PubMed ID: 15510613
[TBL] [Abstract][Full Text] [Related]
9. Influence of combined methylenetetrahydrofolate reductase (MTHFR) and thymidylate synthase enhancer region (TSER) polymorphisms to plasma homocysteine levels in Korean patients with recurrent spontaneous abortion.
Kim NK; Choi YK; Kang MS; Choi DH; Cha SH; An MO; Lee S; Jeung M; Ko JJ; Oh D
Thromb Res; 2006; 117(6):653-8. PubMed ID: 15985285
[TBL] [Abstract][Full Text] [Related]
10. One-carbon metabolism and breast cancer risk: no association of MTHFR, MTR, and TYMS polymorphisms in the GENICA study from Germany.
Justenhoven C; Hamann U; Pierl CB; Rabstein S; Pesch B; Harth V; Baisch C; Vollmert C; Illig T; Brüning T; Ko Y; Brauch H
Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):3015-8. PubMed ID: 16365030
[No Abstract] [Full Text] [Related]
11. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.
Kafka A; Sauer G; Jaeger C; Grundmann R; Kreienberg R; Zeillinger R; Deissler H
Int J Oncol; 2003 May; 22(5):1117-21. PubMed ID: 12684679
[TBL] [Abstract][Full Text] [Related]
12. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
[TBL] [Abstract][Full Text] [Related]
13. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women.
Zubor P; Lasabova Z; Hatok J; Stanclova A; Danko J
Oncol Rep; 2007 Jul; 18(1):211-7. PubMed ID: 17549370
[TBL] [Abstract][Full Text] [Related]
14. A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Terrazzino S; Agostini M; Pucciarelli S; Pasetto LM; Friso ML; Ambrosi A; Lisi V; Leon A; Lise M; Nitti D
Pharmacogenet Genomics; 2006 Nov; 16(11):817-24. PubMed ID: 17047490
[TBL] [Abstract][Full Text] [Related]
15. One-carbon metabolism-related gene polymorphisms and risk of breast cancer.
Suzuki T; Matsuo K; Hirose K; Hiraki A; Kawase T; Watanabe M; Yamashita T; Iwata H; Tajima K
Carcinogenesis; 2008 Feb; 29(2):356-62. PubMed ID: 18174236
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk.
Lima CS; Ortega MM; Ozelo MC; Araujo RC; De Souza CA; Lorand-Metze I; Annichino-Bizzacchi JM; Costa FF
Leuk Res; 2008 Mar; 32(3):401-5. PubMed ID: 17655928
[TBL] [Abstract][Full Text] [Related]
17. No association between methylenetetrahydrofolate reductase C677T polymorphism and breast cancer.
Hekim N; Ergen A; Yaylim I; Yilmaz H; Zeybek U; Oztürk O; Isbir T
Cell Biochem Funct; 2007; 25(1):115-7. PubMed ID: 16134079
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
20. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
Anticancer Res; 2014 Jun; 34(6):3031-7. PubMed ID: 24922669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
